arrow
F

Francesco Perrone

istituto nazionale tumori - irccs - fondazione g. pascale
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial

关于不良中危前列腺癌患者生活质量及勃起功能恢复的研究方案:REDI-CaP试验

2026-08-270
OA
Somatic BRCA1 and BRCA2 detection in Homologous Recombination Deficiency testing: concordance of four sequencing workflows with the Myriad myChoice® companion diagnostic

体细胞BRCA1和BRCA2检测在同源重组缺陷测试中的应用:四种测序工作流与Myriad myChoice®伴随诊断的一致性

2026-06-200
PRE
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模态泛肿瘤细胞游离DNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

2026-02-260
OAAI
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026-01-010
PRE
Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review

年轻成年及成年发病癌症幸存者的晚期内分泌-代谢并发症:全面评估与管理策略。意大利医学肿瘤学会(AIOM)、意大利医学糖尿病学会(AMD)、意大利糖尿病学会(SID)、意大利内分泌学会(SIE)、意大利药理学学会(SIF)多学科批判性综述

2025-12-030
OAAI
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients

纵向验证PROFFIT问卷以评估癌症患者的财务毒性

2025-10-010
OAAI
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica

不同医院在超说明书用药授权方面的异质性:意大利肿瘤学协会(Associazione Italiana di Oncologia Medica)的项目

2025-10-010
PRE
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin plus paclitaxel/avelumab (MITO-END3 trial)

外周单核细胞源性抑制性细胞与单中心接受卡铂联合紫杉醇/阿维单抗治疗子宫内膜癌患者分子亚型的相关性(MITO-END3试验)

2025-04-170
OA
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study

接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

2024-10-160
OAAI
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
BREAST
IF7.9
2024-10-010
OAAI
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (vol 41, 100912, 2024)
2024-09-010
OA
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (Vol 41, 100912, 2024)
2024-07-010
OA
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (vol 41, 100912, 2024)
2024-07-010
OA